Skip to main content

Table 1 Basic characteristics of included studies for plasma tau analysis

From: Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis

Study Subjects (n) Male (%) Age, years (mean ± SD) Plasma tau (pg/ml) Research question Method
Shahim et al. (2014) [27] CN (47) NA 28 ± 14.07 4.5 ± 5.66 1 Simoa
Bogoslovsky et al. (2015) [28] CN (69) 51 45 ± 15.5 4.34 ± 1.77 1 Simoa
Olivera et al. (2015) [29] CN (28) 96.4 28.40 ± 4.47 0.63 ± 0.48 1 Simoa
Dage et al. (2016) [30] CN (378) 61.4 80 ± 5.19 4.14 ± 1.56 1 Simoa
Alosco et al. (2017) [31] CN (25) 100 55.16 ± 7.95 2.46 ± 0.57 1 Simoa
Mielke et al. (2017) [32] CN (335) 62.4 80.8 ± 4.8 4.2 ± 1.5 1 Simoa
Müller et al. (2017) [33] CN (134) 59.7 68.4 ± 5 3.6 ± 1.7 1 Simoa
Kasai et al. (2017) [34] CN (22) 54.5 37.4 ± 12.0 0.470 ± 0.232 1 Simoa
Foiani et al. (2018) [35] CN (22) 41 68.7 ± 6.5 1.67 ± 0.50 1 Simoa
Bergman et al. (2018) [36] CN (36) 0 30 ± 4 6.24 ± 2.76 1 Simoa
Lippa et al. (2018) [37] CN (42) 90.5 36.21 ± 11.69 2.81 ± 1.20 1 Simoa
Verberk et al. (2018) [38] CN (191) 63 59 ± 9 3.18 ± 1.07 1 Simoa
Shahim et al. (2018) [39] CN (19) NA 25.0 ± 8.89 1.8 ± 1.48 1 Simoa
Wallace et al. (2018) [40] CN (13) 100 18.5 ± 1.7 2.56 ± 1.02 1 Simoa
Motamedi et al. (2018) [41] CN (24) 91.7 30.9 ± 7.77 2.48 ± 1.94 1 Simoa
Fortea et al. (2018) [42] CN (67) 30 52.05 ± 5.50 2.23 ± 1.63 1 Simoa
Zeitlberger et al. (2018) [43] CN (13) 46.2 37 2.08 ± 1.23 1 Simoa
Shi et al. (2019) [44] CN (87) 41.4 64.77 ± 7.40 3.56 ± 1.84 1 Simoa
Kitaguchi et al. (2019) [45] CN (11) 45.4 67.8 ± 3.71 0.63 ± 0.3 1 Simoa
Pase et al. (2019) [46] CN (3232) 46.8 58 ± 14 3.93 ± 1.11 1 Simoa
Korley et al. (2019) [47] CN (63) 63.5 39.0 ± 20.7 3.5 ± 3.19 1 Simoa
Kritikos et al. (2020) [48] CN (398) 94.72 54.3 ± 8.1 1.67 ± 0.685 1 Simoa
Wolf et al. (2020) [49] CN (4444) 42 71.9 ± 7.5 2.6 ± 2.3 1 Simoa
Verberk et al. (2020) [50] CN (241) 60 61.9 ± 10 3.1 ± 1 1 Simoa
Pattinson et al. (2020) [51] CN (18) 85.3 35.56 ± 12.39 2.57 ± 1.01 1 Simoa
Romero et al. (2020) [52] CN (3472) 46 54.9 ± 13.2 3.9 ± 1.11 1 Simoa
Petersen et al. (2020) [53] CN (225) 51.5 45.7 ± 7.1 2.4 ± 1.8 1 Simoa
Cantero et al. (2020) [54] CN (57) 47.4 67.7 ± 3.4 3.1 ± 1.5 1 Simoa
Zetterberg et al. (2013) [55] CN (25) 24 74 ± 6.7 4.43 ± 2.83 1 and 2 Simoa
AD (54) 31.5 75 ± 6.2 8.80 ± 10.1
Mattsson et al. (2016) ADNI [56] CN (189) 55 75.9 ± 4.9 2.58 ± 1.19 1 and 2 Simoa
AD (179) 52 75.2 ± 7.4 3.12 ± 1.50
Mattsson et al. (2016) BioFINDER [56] CN (274) 39 72.9 ± 4.9 5.58 ± 2.51 1 and 2 Simoa
AD (61) 42 76.4 ± 4.7 5.37 ± 2.56
Shi et al. (2016) [44] CN (106) 54.7 67.1 ± 7.4 2.405 ± 2.76 1, 2 and 3 Simoa
AD (106) 53.8 69.5 ± 8.1 3.870 ± 2.22
Kovacs et al. (2017) [57] CN (18) 50 73.7 1.68 ± 0.17 1 and 2 Simoa
AD (21) 23.8 77 7.5 ± 3.2
Deters et al. (2017) [58] CN (166) 57.2 75.2 ± 5.1 2.71 ± 1 1 and 2 Simoa
AD (168) 51.8 75.3 ± 7.3 3.13 ± 1.3
Chen et al. (2017) [59] CN (151) 58.9 75.7 ± 4.9 2.7 ± 1.1 1 and 2 Simoa
AD (149) 55.7 76.1 ± 7.3 3.2 ± 1.3
Mielke et al. (2018) [60] CN (172) 69.2 71.9 ± 9.5 5.9 ± 1.90 1 and 2 Simoa
AD (40) 23 67.7 ± 9.2 7.2 ± 2.80
Park et al. (2019) [61] CN (172) 40.4 71.08 ± 1.0 2.37 ± 0.1 1, 2 and 3 Simoa
AD (40) 13.3 75.87 ± 2.1 3.36 ± 0.3
Li et al. (2019) [62] CN (9) 44.4 61.78 ± 10.52 4.62 ± 0.50 1 and 2 Simoa
AD (53) 42.3 68.39 ± 9.65 5.47 ± 2.69
Startin et al. (2019) [63] CN (27) 59.3 49.26 ± 10.40 1.49 ± 1.26 1 and 2 Simoa
AD (27) 66.7 59.33 ± 4.04 1.45 ± 1.02
Sugarman et al. (2020) [64] CN (238) 37.4 72.38 ± 7.69 3.22 ± 2.73 1, 2 and 3 Simoa
AD (156) 55.8 76.74 ± 8.12 3.73 ± 3.01
Fossati et al. (2020) [65] CN (68) 35.3 67.71 ± 8.54 2.74 ± 0.76 1, 2 and 3 Simoa
AD (29) 34.5 72.81 ± 9.69 3.67 ± 1.06
Deniz et al. (2020) [66] CN (162) 23.5 82.7 ± 8.15 3.84 ± 2.27 1 and 2 Simoa
AD (159) 31.2 78.2 ± 8.97 3.75 ± 2.36
Lin et al. (2018) [67] CN (35) 40.0 62.6 ± 9.7 12.12 ± 0.96 1 IMR
Chi et al. (2019) [68] CN (42) 79 59 ± 11.1 18.2 ± 13.78 1 IMR
Chen et al. (2019) [69] CN (13) 69.2 73 ± 13.0 18.7 ± 5.63 1 IMR
Chen et al. (2020) [70] CN (28) 28.6 61.1 ± 4.9 14.67 ± 8.49 1 IMR
Fang et al. (2020) [71] CN -young (43) 67 38.7 ± 13.5 14.9 ± 5.5 1 IMR
CN -old (34) 41 70.3 ± 5.8 15.0 ± 7.3 1
Chiu et al. (2017) [72] CN- middle (56) 29.1 58.1 ± 4.9 14.35 ± 6.49 1 IMR
CN- old (70) 45.7 73.6 ± 6.3 18.14 ± 7.33 1
Chiu et al. (2013) [73] CN (30) 43.3 64.4 ± 9.5 15.6 ± 6.9 1 and 2 IMR
AD (10) 40 69.3 ± 9.4 53.9 ± 11.7
Tzen et al. (2014) [74] CN (20) 50 63.7 ± 7.9 13.5 ± 5.5 1 and 2 IMR
AD (14) 28.6 64.9 ± 11.5 46.7 ± 2.0
Yang et al. (2017) [75] CN (66) NA 64.6 ± 8.6 13.37 ± 7.77 1 and 2 IMR
AD (29) 72.2 ± 9.9 55.44 ± 22.45
Lee et al. (2017) [76] CN-young (44) 68.1 38.4 ± 13.5 14.9 ± 5.5 1 and 2 IMR
CN-old (34) 41.2 70.3 ± 5.8 15.0 ± 7.3
AD (62) 46.8 72.1 ± 11.1 47.5 ± 18.9
Lue et al. (2017) BSHRI [77] CN (16) 25 81.9 ± 1.5 20.48 ± 1.24 1 and 2 IMR
AD (16) 43.8 82.5 ± 1.4 34.52 ± 3.75
Lue et al. (2017) NTUH [77] CN (61) 39.3 64.2 ± 1.1 13.98 ± 1.89 1 and 2 IMR
AD (31) 54.8 72.5 ± 1.8 52.47 ± 2.72
Yang et al. (2018) [78] CN (23) NA 67.5 ± 7.1 18.85 ± 10.16 1 and 2 IMR
AD (21) 78.8 ± 7.9 37.54 ± 12.29
Chiu et al. (2019) BSHRI [79] CN (16) NA 81.9 ± 6 20.48 ± 4.96 1 and 2 IMR
AD (16) 82.5 ± 1.4 34.52 ± 14
Chiu et al. (2019) NTUH [79] CN (37) NA 66.1 ± 8.3 16.61 ± 9.18 1 and 2 IMR
AD (25) 78.1 ± 7.3 43.35 ± 15.14
Jiao et al. (2020) [80] CN (57) 45.6 67.9 ± 9.5 20.65 ± 3.52 1 and 2 IMR
AD (40) 37.5 68.1 ± 9.0 25.91 ± 8.12
Liu et al. (2020) [81] CN (2) 50 37 ± 2.8 17.4 ± 1.1 1 and 2 IMR
AD (3) 33.3 71.3 ± 4.0 28.3 ± 4.0
Rubenstein et al. (2017) [82] CN (20) 70 40.5 ± 14.2 0.063 ± 0.014 1 a-EIMAF
Gardner et al. (2018) [83] CN-young (79) 73.4 25.8 ± 7.3 0.079 ± 0.0087 1 a-EIMAF
CN-middle-aged (60) 66.7 50.0 ± 5.9 0.078 ± 0.008
CN-older (30) 63.3 68.0 ± 8.4 0.079 ± 0.0065
Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us

\